Law & Regulation
Jeffrey Finkle, CEO of Arcview, Sits in the Investor Hotseat on November 30th
Arcview CEO, Jeffrey Finkle, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments. The Arcview Group (TAG)…
Arcview CEO, Jeffrey Finkle, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments.
The Arcview Group (TAG) is an integrated financial services and asset management firm serving the cannabis, industrial hemp, and psychedelics sectors. TAG delivers these services through three operating subsidiaries, Arcview Capital, its broker/dealer, Arcview Ventures, its principal investing group, and Arcview Management Consulting, its consulting division.
TAG is known for its thought leadership delivered through live events, original content production, research, investor pitch nights, and high-profile speakerships.
TAG believes in the incredible value and opportunity, both economic and social, created by these industries. We believe in supporting diversity and inclusion, supporting minorities, marginalized communities, and gender diversification in all aspects of our service offerings.
Will Jeffrey be able to handle the heat in the hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Law & Regulation1 week ago
Relmada Therapeutics trims losses, slashes research costs
-
Psychedelics1 week ago
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Psychedelics1 week ago
Numinus Wellness Submits Clinical Trial Application
-
Psychedelics1 week ago
Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
-
Psychedelics1 week ago
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
-
Psilocybin1 week ago
Indigenous Psilocybin Practices Around the World
-
Psychedelics1 week ago
Psilocybin Study Reveals the Brain Suppresses Reactions To Angry Faces
-
Law & Regulation1 week ago
Gilgamesh secures $14M for ibogaine-like drug